FORA:NASDAQForian Inc. Analysis
Data as of 2026-06-17 - not real-time
$2.17
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Forian Inc. is trading in a narrow range between its identified support and resistance levels, with price perched just below the upper barrier. The short‑term SMA sits marginally above the mid‑term SMA, suggesting a slight bullish bias, yet the MACD histogram is negative and the signal line is flagged as bearish, indicating downward momentum pressure. Momentum remains modestly elevated as reflected by an RSI that is approaching the upper third of its scale, hinting at limited upside before a potential pullback. Fundamentally, the company shows a stark contrast between a healthy cash position and negative profitability metrics, while the forward earnings outlook turns positive, and the discounted cash flow model places fair value well above the current market price, presenting a valuation gap. The sector—health information services—carries moderate regulatory exposure and the stock’s beta is exceptionally low, implying limited market‑wide volatility, though the small market cap and thin trading volume raise liquidity considerations. Overall, the technical setup suggests caution in the very short run, but the valuation disparity and improving earnings outlook provide a catalyst for medium‑ to long‑term investors.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- price near resistance with bearish MACD signal
- RSI approaching overbought territory
- limited short‑term upside given current momentum
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value substantially above market price
- forward earnings turning positive
- low beta indicating defensive profile in a volatile market
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- persistent cash cushion offsetting earnings volatility
- sector growth potential in health data analytics
- ongoing liquidity constraints limiting rapid price appreciation
Key Metrics & Analysis
Financial Health
Revenue Growth-2.90%
Profit Margin-17.00%
P/E Ratio24.1
ROE-17.95%
ROA-8.37%
Debt/Equity0.02
P/B Ratio2.3
Op. Cash Flow$1.9M
Free Cash Flow$4.2M
Industry P/E24.3
Technical Analysis
TrendNeutral
RSI64.0
Support$2.15
Resistance$2.18
MA 20$2.16
MA 50$2.12
MA 200$2.13
MACDBearish
VolumeStable
Fear & Greed Index88.5
Valuation
Fair Value$2.77
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.15
Volatility8.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.